The impact of early cytomegalovirus infection and disease in renal transplant recipients

Clinical Microbiology and Infection

Volumn 11, Issue 7, 2005, Pages 518-530

  Sagedal, Solbjorg ^a   Hartmann, A ^a   Rollag, H ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cytomegalovirus disease; Human cytomegalovirus; Kidney graft rejection; Patient survival; Review; Transplantation

Indexed keywords

ACICLOVIR; AZATHIOPRINE; CYTOMEGALOVIRUS ANTIGEN PP65; GANCICLOVIR; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; THYMOCYTE ANTIBODY; VALACICLOVIR; VALGANCICLOVIR; VIRUS DNA;

ACUTE GRAFT REJECTION; ANTIGEN DETECTION; ATHEROSCLEROSIS; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG RESPONSE; FREQUENCY ANALYSIS; GRAFT SURVIVAL; HEART TRANSPLANTATION; HERPES VIRUS INFECTION; HUMAN; HUMAN CYTOMEGALOVIRUS; INFECTION PREVENTION; KIDNEY DONOR; KIDNEY TRANSPLANTATION; LONG TERM CARE; MORTALITY; POLYMERASE CHAIN REACTION; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION; STAPHYLOCOCCUS INFECTION; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS LOAD;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5;

EID: 21244444619     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2005.01190.x     Document Type: Review

References (104)

1. Yang CW, Kim YO, Kim YS et al. Clinical course of cytomegalovirus (CMV) viremia with and without ganciclovir treatment in CMV-seropositive kidney transplant recipients. Longitudinal follow-up of CMV pp65 antigenemia assay. Am J Nephrol 1998; 18: 373-378.
2. Toupance O, Bouedjoro-Camus MC, Carquin J et al. Cytomegalovirus-related disease and risk of acute rejection in renal transplant recipients: a cohort study with case-control analyses. Transplant Int 2000; 13: 413-419.
3. Hokeberg I, Eriksson BM, Zweygberg-Wirgart B, Tufvesson G, Olding-Stenkvist E, Grillner L. Diagnostic markers and risk factors of cytomegalovirus infection and disease in renal allograft recipients. Scand J Infect Dis 1995; 27: 435-440.
4. Sagedal S, Nordal KP, Hartmann A et al. A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients. Transplantation 2000; 70: 1166-1174.
5. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097.
6. Degre M, Kristiansen KI, Rollag H, Holter E, Nordal KP. Detection of human cytomegalovirus (HCMV) pp67-mRNA and pp65 antigenemia in relation to development of clinical HCMV disease in renal transplant recipients. Clin Microbiol Infect 2001; 7: 254-260.
7. Lo CY, Ho KN, Yuen KY et al. Diagnosing cytomegalovirus disease in CMV seropositive renal allograft recipients: a comparison between the detection of CMV DNAemia by polymerase chain reaction and antigenemia by CMV pp65 assay. Clin Transplant 1997; 11: 286-293.
8. Hassan-Walker AF, Kidd IM, Sabin C, Sweny P, Griffiths PD, Emery VC. Quantity of human cytomegalovirus (CMV) DNAemia as a risk factor for CMV disease in renal allograft recipients: relationship with donor/recipient CMV serostatus, receipt of augmented methylprednisolone and antithymocyte globulin (ATG). J Med Virol 1999; 58: 182-187.
9. Kim CK, Song JH, Kim SM et al. Clinical usefulness of human cytomegalovirus antigenemia assay after kidney transplantation. Transplantation 2003; 75: 2151-2155.
10. Humar A, Paya C, Pescovitz MD et al. Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R- solid organ transplant recipients. Am J Transplant 2004; 4: 644-649.
11. Humar A, Kumar D, Boivin G, Caliendo AM. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis 2002; 186: 829-833.
12. Sarmiento JM, Munn SR, Paya CV, Velosa JA, Nguyen JH. Is cytomegalovirus infection related to mycophenolate mofetil after kidney transplantation? A case-control study. Clin Transplant 1998; 12: 371-374.
13. Rubin RH, Kemmerly SA, Conti D et al. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Transplant Infect Dis 2000; 2: 112-117.
14. Abbott KC, Hypolite IO, Viola R et al. Hospitalizations for cytomegalovirus disease after renal transplantation in the United States. Ann Epidemiol 2002; 12: 402-409.
15. Hibberd PL, Tolkoff-Rubin NE, Cosimi AB et al. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation 1992; 53: 68-72.
16. Yeung S, Tong KL, Chan HW. Impact of OKT3 and polyclonal antibodies on symptomatic CMV infection in renal transplant recipients. Transplant Proc 2000; 32: 1928-1929.
17. Kusne S, Shapiro R, Fung J. Prevention and treatment of cytomegalovirus infection in organ transplant recipients. Transplant Infect Dis 1999; 1: 187-203.
18. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000; 355: 2032-2036.
19. Rollag H, Sagedal S, Kristiansen KI et al. Cytomegalovirus DNA concentration in plasma predicts development of cytomegalovirus disease in kidney transplant recipients. Clin Microbiol Infect 2002; 8: 431-434.
20. Sarmiento JM, Dockrell DH, Schwab TR, Munn SR, Paya CV. Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients. Clin Transplant 2000; 14: 136-138.
21. ter Meulen CG, Wetzels JF, Hilbrands LB. The influence of mycophenolate mofetil on the incidence and severity of primary cytomegalovirus infections and disease after renal transplantation. Nephrol Dial Transplant 2000; 15: 711-714.
22. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60: 225-232.
23. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321-1325.
24. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029-1037.
25. Giral M, Nguyen JM, Daguin P et al. Mycophenolate mofetil does not modify the incidence of cytomegalovirus (CMV) disease after kidney transplantation but prevents CMV-induced chronic graft dysfunction. J Am Soc Nephrol 2001; 12: 1758-1763.
26. Kashyap R, Shapiro R, Jordan M, Randhawa PS. The clinical significance of cytomegaloviral inclusions in the allograff kidney. Transplantation 1999; 67: 98-103.
27. Neyts J, Andrei G, De Clercq E. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo. Antimicrob Agents Chemother 1998; 42: 216-222.
28. Sagedal S, Nordal KP, Hartmann A et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002; 2: 850-856.
29. Pouteil-Noble C, Ecochard R, Landrivon G et al. Cytomegalovirus infection - an etiological factor for rejection? A prospective study in 242 renal transplant patients. Transplantation 1993; 55: 851-857.
30. von Willebrand E, Pettersson E, Ahonen J, Hayry P. CMV infection, class II antigen expression, and human kidney allograft rejection. Transplantation 1986; 42: 364-367.
31. Lowance D, Neumayer HH, Legendre CM et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999; 340: 1462-1470.
32. Opelz G, Dohler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4: 928-936.
33. Payton D, Thorner P, Eddy A, Yeger H, Baumal R. Demonstration by light microscopy of cytomegalovirus on a renal biopsy of a renal allograft recipient: confirmation by immunohistochemistry and in situ hybridization. Nephron 1987; 47: 205-208.
34. Cameron J, Rigby RJ, van Deth AG, Petrie JJ. Severe tubulo-interstitial disease in a renal allograft due to cytomegalovirus infection. Clin Nephrol 1982; 18: 321-325.
35. Liapis H, Storch GA, Hill DA, Rueda J, Brennan DC. CMV infection of the renal allograft is much more common than the pathology indicates: a retrospective analysis of qualitative and quantitative buffy coat CMV-PCR, renal biopsy pathology and tissue CMV-PCR. Nephrol Dial Transplant 2003; 18: 397-402.
36. Shaver MJ, Bonsib SM, Abul-Ezz S, Barri YM. Renal allograft dysfunction associated with cytomegalovirus infection. Am J Kidney Dis 1999; 34: 942-946.
37. Reinke P, Fietze E, Ode-Hakim S et al. Late-acute renal allograft rejection and symptomless cytomegalovirus infection. Lancet 1994; 344: 1737-1738.
38. Onuigbo M, Haririan A, Ramos E, Klassen D, Wali R, Drachenberg C. Cytomegalovirus-induced glomerular vasculopathy in renal allografts: a report of two cases. Am J Transplant 2002; 2: 684-688.
39. Boyce NW, Hayes K, Gee D et al. Cytomegalovirus infection complicating renal transplantation and its relationship to acute transplant glomerulopathy. Transplantation 1988; 45: 706-709.
40. Humar A, Gillingham KJ, Payne WD, Dunn DL, Sutherland DE, Matas AJ. Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients. Transplantation 1999; 68: 1879-1883.
41. Sagedal S, Hartmann A, Nordal KP et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004; 66: 329-337.
42. Lim EC, Terasaki PI. Outcome of kidney transplantation in different diseases. Clin Transplant 1990; 4: 461-469.
43. Fernandez-Fresnedo G, Zubimendi JA, Cotorruelo JG et al. Significance of age in the survival of diabetic patients after kidney transplantation. Int Urol Nephrol 2002; 33: 173-177.
44. Hartmann A, Holdaas H, Fauchald P et al. Fifteen years' experience with renal transplantation in systemic amyloidosis. Transplant Int 1992; 5: 15-18.
45. Hjelmesaeth J, Hartmann A, Kofstad J et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 1997; 64: 979-983.
46. Hjelmesaeth J, Jenssen T, Hagen M, Egeland T, Hartmann A. Determinants of insulin secretion after renal transplantation. Metabolism 2003; 52: 573-578.
47. Hjelmesaeth J, Sagedal S, Hartmann A et al. Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation. Diabetologia 2004; 47: 1550-1556.
48. Danziger-Isakov LA, DelaMorena M, Hayashi RJ et al. Cytomegalovirus viremia associated with death or retransplantation in pediatric lung-transplant recipients. Transplantation 2003; 75: 1538-1543.
49. de Otero J, Gavalda J, Murio E et al. Cytomegalovirus disease as a risk factor for graft loss and death after orthotopic liver transplantation. Clin Infect Dis 1998; 26: 865-870.
50. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989; 261: 3561-3566.
51. McDonald K, Rector TS, Braulin EA, Kubo SH, Olivari MT. Association of coronary artery disease in cardiac transplant recipients with cytomegalovirus infection. Am J Cardiol 1989; 64: 359-362.
52. Zhou YF, Leon MB, Waclawiw MA et al. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med 1996; 335: 624-630.
53. Blum A, Giladi M, Weinberg M et al. High anti-cytomegalovirus (CMV) IgG antibody titer is associated with coronary artery disease and may predict post-coronary balloon angioplasty restenosis. Am J Cardiol 1998; 81: 866-868.
54. Neumann FJ, Kastrati A, Miethke T et al. Previous cytomegalovirus infection and restenosis after coronary stent placement. Circulation 2001; 104: 1135-1139.
55. Hernandez D, Hanson E, Kasiske MK, Danielson B, Roel J, Kasiske BL. Cytomegalovirus disease is not a major risk factor for ischemic heart disease after renal transplantation. Transplantation 2001; 72: 1395-1399.
56. Espinola-Klein C, Rupprecht HJ, Blankenberg S et al. Impact of infectious burden on progression of carotid atherosclerosis. Stroke 2002; 33: 2581-2586.
57. Ridker PM, Hennekens CH, Stampfer MJ, Wang F. Prospective study of herpes simplex virus, cytomegalovirus, and the risk of future myocardial infarction and stroke. Circulation 1998; 98: 2796-2799.
58. Grahame-Clarke C, Chan NN, Andrew D et al. Human cytomegalovirus seropositivity is associated with impaired vascular function. Circulation 2003; 108: 678-683.
59. Nett PC, Heisey DM, Fernandez LA, Sollinger HW, Pirsch JD. Association of cytomegalovirus disease and acute rejection with graft loss in kidney transplantation. Transplantation 2004; 78: 1036-1041.
60. Rubin RH. Impact of cytomegalovirus infection on organ transplant recipients. Rev Infect Dis 1990; 12(suppl): 754-766.
61. DesJardin JA, Gibbons L, Cho E et al. Human herpesvirus 6 reactivation is associated with cytomegalovirus infection and syndromes in kidney transplant recipients at risk for primary cytomegalovirus infection. J Infect Dis 1998; 178: 1783-1786.
62. Yoshikawa T, Asano Y, Ihira M et al. Human herpesvirus 6 viremia in bone marrow transplant recipients: clinical features and risk factors. J Infect Dis 2002; 185: 847-853.
63. Tong CY, Bakran A, Williams H, Cheung CY, Peiris JS. Association of human herpesvirus 7 with cytomegalovirus disease in renal transplant recipients. Transplantation 2000; 70: 213-216.
64. Osman HK, Peiris JS, Taylor CE, Warwicker P, Jarrett RF, Madeley CR. 'Cytomegalovirus disease' in renal allograft recipients: is human herpesvirus 7 a co-factor for disease progression? J Med Virol 1996; 48: 295-301.
65. Kidd IM, Clark DA, Sabin CA et al. Prospective study of human betaherpesviruses after renal transplantation: association of human herpesvirus 7 and cytomegalovirus co-infection with cytomegalovirus disease and increased rejection. Transplantation 2000; 69: 2400-2404.
66. Mendez JC, Dockrell DH, Espy MJ et al. Human betaherpesvirus interactions in solid organ transplant recipients. J Infect Dis 2001; 183: 179-184.
67. Meyer T, Scholz D, Warnecke G et al. Importance of simultaneous active cytomegalovirus and Epstein-Barr virus infection in renal transplantation. Clin Diagn Virol 1996; 6: 79-91.
68. Manez R, Breinig MC, Linden P et al. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease. J Infect Dis 1997; 176: 1462-1467.
69. Shahinian VB, Muirhead N, Jevnikar AM et al. Epstein-Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoproliferative disorder in adult renal allograft recipients. Transplantation 2003; 75: 851-856.
70. Malouf MA, Chhajed PN, Hopkins P, Plit ML, Glanville A. Antiviral prophylaxis prevents lymphoprofilerative disease in lung transplant recipients. J Heart Lung Transplant 2001; 20: 200.
71. Singh N, Yu VL, Mieles L, Wagener MM, Miner RC, Gayowski T. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial. Ann Intern Med 1994; 120: 375-381.
72. Sagedal S, Nordal KP, Hartmann A et al. Pre-emptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganciclovir: a randomized, comparative study. Nephrol Dial Transplant 2003; 18: 1899-1908.
73. Rayes N, Seehofer D, Schmidt CA et al. Prospective randomized trial to assess the value of preemptive oral therapy for CMV infection following liver transplantation. Transplantation 2001; 72: 881-885.
74. Akposso K, Rondeau E, Haymann JP, Peraldi MN, Marlin C, Sraer JD. Long-term prognosis of renal transplantation after preemptive treatment of cytomegalovirus infection. Transplantation 1997; 63: 974-976.
75. Hibberd PL, Tolkoff-Rubin NE, Conti D et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial. Ann Intern Med 1995; 123: 18-26.
76. Gomez E, de Ona M, Aguado S et al. Cytomegalovirus preemptive therapy with ganciclovir in renal transplant patients treated with OKT3. Nephron 1996; 74: 367-372.
77. Conti DJ, Freed BM, Singh TP, Gallichio M, Gruber SA, Lempert N. Preemptive ganciclovir therapy in cytomegalovirus-seropositive renal transplant recipients. Arch Surg 1995; 130: 1217-1221.
78. Knipe DM, Howley PM, Crumpacker C, eds. Fields virology. Philadelphia: Lippincott Williams & Wilkins, 2002.
79. Talarico CL, Burnette TC, Miller WH et al. Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein. Antimicrob Agents Chemother 1999; 43: 1941-1946.
80. Flechner SM, Avery RK, Fisher R et al. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Transplantation 1998; 66: 1682-1688.
81. Paya C, Humar A, Dominguez E et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611-620.
82. Fiddian P, Sabin CA, Griffiths PD. Valacyclovir provides optimum acyclovir exposure for prevention of cytomegalovirus and related outcomes after organ transplantation. J Infect Dis 2002; 186(suppl): 110-115.
83. Couchoud C, Cucherat M, Haugh M, Pouteil-Noble C. Cytomegalovirus prophylaxis with antiviral agents in solid organ transplantation: a meta-analysis. Transplantation 1998; 65: 641-647.
84. Snydman DR, Werner BG, Heinze-Lacey B et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 1987; 317: 1049-1054.
85. Geddes CC, Church CC, Collidge T et al. Management of cytomegalovirus infection by weekly surveillance after renal transplant: analysis of cost, rejection and renal function. Nephrol Dial Transplant 2003; 18: 1891-1898.
86. Anonymous. European Best Practice Guidelines for Renal Transplantation (part 1). Nephrol Dial Transplant 2000; 15(suppl): 1-85.
87. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus; disease among recipients of solid-organ transplants. Lancet 2000; 356: 645-649.
88. Alain S, Hantz S, Scieux C et al. Detection of ganciclovir resistance after valacyclovir-prophylaxis in renal transplant recipients with active cytomegalovirus infection. J Med Virol 2004; 73: 566-573.
89. Boivin G, Goyette N, Gilbert C et al. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis 2004; 189: 1615-1618.
90. Boivin G, Gilbert C, Gaudreau A, Greenfield I, Sudlow R, Roberts NA. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. J Infect Dis 2001; 184: 1598-1602.
91. Limaye AP, Raghu G, Koelle DM, Ferrenberg J, Huang ML, Boeckh M. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 2002; 185: 20-27.
92. Becker BN, Becker YT, Leverson GE, Simmons WD, Sollinger HW, Pirsch JD. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation. Am J Kidney Dis 2002; 39: 1088-1095.
93. Dickenmann MJ, Cathomas G, Steiger J, Mihatsch TMJ, Thiel G, Tamm M. Cytomegalovirus infection and graft rejection in renal transplantation. Transplantation 2001; 71: 764-767.
94. Fryd DS, Peterson PK, Ferguson RM, Simmons RL, Balfour HH, Najarian JS. Cytomegalovirus as a risk factor in renal transplantation. Transplantation 1980; 30: 436-439.
95. Eriksson BM, Wirgart BZ, Claesson K et al. A prospective study of rapid methods of detecting cytomegalovirus in the blood of renal transplant recipients in relation to patient and graft survival. Clin Transplant 1996; 10: 494-502.
96. Schnitzler MA, Lowell JA, Hmiel SP et al. Cytomegalovirus disease after prophylaxis with oral ganciclovir in renal transplantation: the importance of HLA-DR matching. J Am Soc Nephrol 2003; 14: 780-785.
97. Brennan DC, Garlock KA, Lippmann BA et al. Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy. J Am Soc Nephrol 1997; 8: 118-125.
98. Gotti E, Suter F, Baruzzo S, Perani V, Moioli F, Remuzzi G. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia. Clin Transplant 1996; 10: 550-555.
99. Koetz AC, Delbruck R, Furtwangler A et al. Cytomegalovirus pp65 antigen-guided preemptive therapy with ganciclovir in solid organ transplant recipients: a prospective, double-blind, placebo-controlled study. Transplantation 2001; 72: 1325-1327.
100. Balfour HH, Chace BA, Stapleton JT, Simmons RL, Fryd DS. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989; 320: 1381-1387.
101. Ahsan N, Holman MJ, Yang HC. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients. Clin Transplant 1997; 11: 633-639.
102. Kletzmayr J, Kotzmann H, Popow-Kraupp T, Kovarik J, Klauser R. Impact of high-dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients. J Am Soc Nephrol 1996; 7: 325-330.
103. Brennan DC, Garlock KA, Singer GG et al. Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients. Transplantation 1997; 64: 1843-1846.
104. Rondeau E, Bourgeon B, Peraldi MN et al. Effect of prophylactic ganciclovir on cytomegalovirus infection in renal transplant recipients. Nephrol Dial Transplant 1993; 8: 858-862.